Physician profile
Anna Elder
NPI 1912430273
$821.25
in general payments reported to CMS, 2019-2025
14 companies · $280 in 2025
The $280 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $142 · 2023: $229 · 2024: $170 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $294.08 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $140.44 | 2022-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $100.35 | 2022-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Collegium Pharmaceutical, INC. | $46.09 | 2025 | Jornay Pm |
| Ultragenyx Pharmaceutical INC. | $43.10 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $41.95 | 2025 | Zoryve |
| Supernus Pharmaceuticals, INC. | $28.25 | 2022 | |
| Kyowa Kirin, INC. | $24.40 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.92 | 2025 | Alvesco |
| Dexcom, INC. | $18.67 | 2023 | Dexcom G6 Transmitter |
| Seqirus USA INC | $16.52 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.44 | 2023 | Gattex |
| Sanofi Pasteur INC. | $15.10 | 2025 | |
| Glaxosmithkline, LLC. | $14.94 | 2025 | Penmenvy, Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Elder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.